Fig. 4

Survival benefit conferred by the combination therapy is superior to chemotherapy or immunotherapy alone and strongly influenced by dosing schedule. Different dosing schedules were tested to understand the temporal interaction between chemotherapy and immunotherapy in ID8-Vegf-Defb29-tumor bearing mice. Each is depicted above the Kaplan-Meier curves. a A Kaplan-Meier curve is shown comparing combination therapy (Combo) to chemotherapy (Chemo) or immunotherapy (IT) alone as well as vehicle only (Vehicle). b A Kaplan-Meier curve is shown comparing 3 weeks of treatment (Combo) to 1 week of immunotherapy treatment (Combo short) following chemotherapy. c A Kaplan-Meier curve is shown comparing immunotherapy initiated on the same day as chemotherapy (Combo) to immunotherapy initiated 4 days later (Delayed IT). d A Kaplan-Meier curve is shown comparing combination therapy initiated on day 8 (Combo) to combination therapy initiated on day 22 (Combo late). b-d Treatment groups are compared to chemotherapy and isotype control (Chemo). The number of mice per group (n) and median survival (ms) are listed. All experiments were performed with biological replicates at least twice. Statistics were calculated using the Log-rank (Mantel-Cox) test. *** p ≤ 0.001, **** p ≤ 0.0001